<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104830</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-017-3</org_study_id>
    <nct_id>NCT02104830</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients</brief_title>
  <official_title>Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare safety and efficacy of a single dose of
      empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients
      receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence of
      CTCAE grade 3/4 neutropenia after a single administration of recombinant human pegylated
      filgrastim empegfilgrastim (Extimia®) at a dose of 6 or 7.5 mg versus daily administration of
      filgrastim at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer patients
      receiving myelosuppressive chemotherapy.

      The study also includes the following determination of pharmacokinetic parameters after
      repeated administration of the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Neutropenia CTCAE Grade 4</measure>
    <time_frame>3 weeks</time_frame>
    <description>The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);</measure>
    <time_frame>2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Severe Neutropenia (Grade 3-4)</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Level (Nadir) ANC x 10^9/L</measure>
    <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutropenia Duration, Any Grade</measure>
    <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration From ANC Nadir to ANC &lt; 2.0 x 10^9/L</measure>
    <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Empegfilgrastim 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empegfilgrastim 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Empegfilrastim 6 mg</intervention_name>
    <description>Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.</description>
    <arm_group_label>Empegfilgrastim 6 mg</arm_group_label>
    <other_name>Extimia</other_name>
    <other_name>metpegfilgrastim</other_name>
    <other_name>pegylated filgrastim</other_name>
    <other_name>peg-GCSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.</description>
    <arm_group_label>Filgrastim</arm_group_label>
    <other_name>GCSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo №1</intervention_name>
    <description>Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
    <arm_group_label>Filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo №2</intervention_name>
    <description>Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
    <arm_group_label>Empegfilgrastim 6 mg</arm_group_label>
    <arm_group_label>Empegfilgrastim 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Empegfilrastim 7.5 mg</intervention_name>
    <description>Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.</description>
    <arm_group_label>Empegfilgrastim 7.5 mg</arm_group_label>
    <other_name>Extimia</other_name>
    <other_name>metpegfilgrastim</other_name>
    <other_name>pegylated filgrastim</other_name>
    <other_name>peg-GCSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form;

          -  Histologically verified diagnosis of stage IIb/III/IV breast cancer;

          -  Age of 18-70 years inclusive;

          -  Life expectancy of at least 6 months after inclusion in the study;

          -  If the patient had received the chemotherapy for breast cancer, it should be finished
             30 days before the beginning of the study;

          -  ECOG Performance Status of 0- 2, not increasing within during 2 weeks before
             randomization;

          -  ANC level of 1500/μL and more at the beginning of the study

          -  Platelet count of 100 000/μL and more at the beginning of the study

          -  Hemoglobin level of 90 g/l and more

          -  Creatinine level &lt;1.5 mg/dl

          -  Total bilirubin level &lt;1.5 × the upper limit of normal (ULN)

          -  ALT and/or AST levels &lt;2.5×ULN (5×ULN for patients with liver metastases);

          -  Alkaline phosphatase &lt;5×ULN;

          -  Left ventricular ejection fraction &gt;50% and more;

          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose
             of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for
             epirubicin,if in this study planned 6 cycles of chemotherapy ;

          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose
             of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for
             epirubicin,if in this study planned 4 cycles of chemotherapy ;

          -  Ability of the participant to follow the protocol requirements, according to the
             Investigator's opinion;

          -  Patients of childbearing potential must implement reliable contraceptive measures
             during the study treatment, starting 4 weeks prior randomization and for 6 months
             after the last administration of the study drug;

          -  Patients should be able to follow the Protocol procedures (according to Investigator's
             assessment.

        Exclusion Criteria:

          -  Patient has received two or more chemotherapy regimens for the metastatic breast
             cancer;

          -  Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin,
             dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.

          -  Pregnancy or breastfeeding;

          -  Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim
             administration;

          -  Concomitant radiotherapy (except selective radiotherapy of bone metastases);

          -  Surgery, radiotherapy (except selective radiotherapy of bone metastases),
             administration of any experimental drugs within 30 days prior randomization;

          -  History of bone marrow/stem cell transplantation;

          -  Conditions limiting the patient's ability to follow the protocol;

          -  CTCAE grade 3-4 neuropathy;

          -  HIV, HCV, HBV, T.Pallidum infection(s);

          -  Acute or active chronic infections;

          -  Severe concurrent diseases (for example, severe arterial hypertension, severe heart
             failure, and other);

          -  Severe depression, schizophrenia, any other mental disorders;

          -  Obstacles in intravenous administration of study drugs;

          -  Simultaneous participation in other clinical trials, previous participation in other
             clinical trials within 30 days before entering into the trial, previous participation
             in the same trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biocad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larisa Bolotina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Institution &quot;Moscow Research Oncological Institute P.A.Gertsena &quot;of the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Brichkova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Regional Oncology Dispensary №1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Burdaeva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Arkhangelsk region &quot;Arkhangelsk Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byakhov Michael, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-governmental healthcare institution &quot;Central Clinical Hospital № 2 Semashko&quot; JSC &quot;Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Vladimirov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Stavropol area &quot;Piatigorsky Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinat Galiulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State budget healthcare institution Omsk region &quot;Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oleg Gladkov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Chelyabinsk Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Davydenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Clinical Oncology Dispensary № 1&quot; of the Ministry of Health of the Krasnodar area</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Elkova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Voronezh Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Lifirenko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Kursk Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadezhda Kovalenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Volgograd regional oncologic dispensary № 3&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kopp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Samara Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bogdan Kotiv, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Military medical Academy named after S. M. Kirov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Levchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Stavropol area &quot;Stavropol Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Matrosova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Nizhny Novgorod Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guzel Mukhametshina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Republican Clinical Oncology Dispensary&quot; of the Ministry of Health of the Republic of Tatarstan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Panchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Pecheny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional State Health Care Institution &quot;Orlovsky Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Pimenov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution health care &quot;Tula Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Sinykov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution of Tyumen Region &quot;Regional Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavel Skopin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Educational Institution of Higher Professional Education &quot;Mordovia State University N.P. Ogareva &quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniil Stroyakovsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Tyulyandin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Russian Oncological Scientific Center N.N.Blokhin&quot; Russian Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitriy Udovica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Oncologic Dispensary № 2&quot; Health Department of Krasnodar Area</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Horinko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Perm Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petr Krivorotko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Petrov Oncology Research Center of the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yulia Shapovalova, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-governmental healthcare institution &quot;Chelyabinsk Road Clinical Hospital&quot; JSC &quot;Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludmila Sheveleva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Volgograd Regional Clinical Oncology Dispensary № 1&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vadim Shirinkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Orenburg Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shekar Patil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangalore Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasad Narayanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mazumdar Shaw Cancer Center and Narayana Hrudayalaya Multispecialty Hosptial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nalini Kilara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S.Ramaiah Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Kulik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donetsk City Municipal Oncology Dispensary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Sedakov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donetsk Regional oncology centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Rusin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zakarpatskii Regional Clinical Oncology Dispensary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Vinnik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kharkiv Regional Clinical Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Odarchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinnitskii Regional Oncology Dispensary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkhangelsk District Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital at Chelyabinsk Railway Station</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Republican Clinical Oncology Dispensary&quot; of the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental healthcare institution &quot;Central Clinical Hospital № 2 Semashko&quot; JSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Nizhny Novgorod Regional Oncology Dispensary&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Region Oncology Dispensary</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncology Center</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Educational Institution of Higher Professional Education &quot;Mordovia State University N.P. Ogareva &quot;</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov Oncology Research Center</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Oncology Dispensary №3</name>
      <address>
        <city>Volgograd</city>
        <zip>404130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Volgograd Regional Clinical Oncology Dispensary № 1&quot;</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Ukraine</country>
  </removed_countries>
  <link>
    <url>http://www.biocad.ru</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>August 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2016</results_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>empegfilgrastim</keyword>
  <keyword>pegylated filgrastim</keyword>
  <keyword>neutropenia</keyword>
  <keyword>febrile neutropenia</keyword>
  <keyword>chemotherapy-associated neutropenia</keyword>
  <keyword>breast cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>7 patients were withdrawn for various reasons without receiving any dose of any of the studied products.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Empegfilgrastim 6 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
        </group>
        <group group_id="P2">
          <title>Empegfilgrastim 7.5 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
        </group>
        <group group_id="P3">
          <title>Filgrastim</title>
          <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Empegfilgrastim 6 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
empegfilrastim 6 mg: Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
        </group>
        <group group_id="B2">
          <title>Empegfilgrastim 7.5 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
empegfilrastim 7.5 mg: Empegfilgrastim is supplied as solution for injection 3 mg/ml.
Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.</description>
        </group>
        <group group_id="B3">
          <title>Filgrastim</title>
          <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml ubcutaneously, 24 h after the chemotherapy.
filgrastim: Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="128"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.38" spread="11.07"/>
                    <measurement group_id="B2" value="50.42" spread="9.19"/>
                    <measurement group_id="B3" value="51.86" spread="9.68"/>
                    <measurement group_id="B4" value="50.23" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histologic type</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Infiltrative ductal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltrative lobular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medullar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infiltrative not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low-grade differentiated carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease stage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IIIС</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History previous therapy of breast cancer</title>
          <description>Patients with previous therapy could be treated with several different types of therapy (for example surgery treatment and adjuvant chemotherapy)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adjuvant chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoadjuvant chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormone therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of a disease</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.14" lower_limit="1.0" upper_limit="144.0"/>
                    <measurement group_id="B2" value="11.62" lower_limit="1.0" upper_limit="144.0"/>
                    <measurement group_id="B3" value="5.37" lower_limit="1.0" upper_limit="51.0"/>
                    <measurement group_id="B4" value="11.0" lower_limit="1.0" upper_limit="144.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Neutropenia CTCAE Grade 4</title>
        <description>The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).</description>
        <time_frame>3 weeks</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Neutropenia CTCAE Grade 4</title>
          <description>The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).</description>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.905" spread="1.206"/>
                    <measurement group_id="O2" value="0.791" spread="1.013"/>
                    <measurement group_id="O3" value="1.725" spread="1.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);</title>
        <time_frame>2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);</title>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2nd cycle (week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.452" spread="1.194"/>
                    <measurement group_id="O2" value="0.326" spread="0.919"/>
                    <measurement group_id="O3" value="0.925" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd cycle (week 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.244" spread="0.734"/>
                    <measurement group_id="O2" value="0.310" spread="0.680"/>
                    <measurement group_id="O3" value="0.641" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th cycle (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.195" spread="0.601"/>
                    <measurement group_id="O2" value="0.475" spread="1.320"/>
                    <measurement group_id="O3" value="0.892" spread="1.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Severe Neutropenia (Grade 3-4)</title>
        <time_frame>16 weeks</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Severe Neutropenia (Grade 3-4)</title>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Level (Nadir) ANC x 10^9/L</title>
        <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Level (Nadir) ANC x 10^9/L</title>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>cells x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st cycle (week 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.68"/>
                    <measurement group_id="O2" value="0.91" spread="1.11"/>
                    <measurement group_id="O3" value="0.47" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd cycle (week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.44" spread="1.30"/>
                    <measurement group_id="O2" value="2.10" spread="1.78"/>
                    <measurement group_id="O3" value="0.87" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd cycle (week 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="1.39"/>
                    <measurement group_id="O2" value="1.88" spread="1.71"/>
                    <measurement group_id="O3" value="0.94" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th cycle (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.12"/>
                    <measurement group_id="O2" value="2.07" spread="1.75"/>
                    <measurement group_id="O3" value="0.75" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutropenia Duration, Any Grade</title>
        <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutropenia Duration, Any Grade</title>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st cycle (week 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.214" spread="1.152"/>
                    <measurement group_id="O2" value="1.953" spread="1.194"/>
                    <measurement group_id="O3" value="4.0" spread="3.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd cycle (week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.881" spread="2.276"/>
                    <measurement group_id="O2" value="1.233" spread="1.702"/>
                    <measurement group_id="O3" value="2.775" spread="2.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd cycle (week 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.585" spread="1.897"/>
                    <measurement group_id="O2" value="1.024" spread="1.199"/>
                    <measurement group_id="O3" value="2.487" spread="2.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th cycle (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.146" spread="1.195"/>
                    <measurement group_id="O2" value="1.525" spread="2.364"/>
                    <measurement group_id="O3" value="2.919" spread="2.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration From ANC Nadir to ANC &lt; 2.0 x 10^9/L</title>
        <time_frame>1st cycle (week 3), 2nd cycle (week 6), 3rd cycle (week 9), 4th cycle (week 12)</time_frame>
        <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Empegfilgrastim 6 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O2">
            <title>Empegfilgrastim 7.5 mg</title>
            <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
          </group>
          <group group_id="O3">
            <title>Filgrastim</title>
            <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration From ANC Nadir to ANC &lt; 2.0 x 10^9/L</title>
          <population>The efficacy analysis included only those patients who received at least one dose of study drug, and who were participated in the study for 2 weeks or more.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1st cycle (week 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.98"/>
                    <measurement group_id="O2" value="1.51" spread="0.86"/>
                    <measurement group_id="O3" value="2.98" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd cycle (week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.29"/>
                    <measurement group_id="O2" value="1.05" spread="1.31"/>
                    <measurement group_id="O3" value="2.05" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd cycle (week 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.21"/>
                    <measurement group_id="O2" value="0.98" spread="0.90"/>
                    <measurement group_id="O3" value="1.90" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4th cycle (week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.05"/>
                    <measurement group_id="O2" value="1.03" spread="1.20"/>
                    <measurement group_id="O3" value="2.14" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 month</time_frame>
      <desc>In general, any AEs were reported in all patients in both groups over a period of study. The vast majority of AEs were due to myelosuppressive chemotherapy. When comparing the frequency of registration of individual AEs there was no significant difference. AEs specific for all G-CSF drugs were observed rarely.</desc>
      <group_list>
        <group group_id="E1">
          <title>Empegfilgrastim 6 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
        </group>
        <group group_id="E2">
          <title>Empegfilgrastim 7.5 mg</title>
          <description>Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy
Placebo №2: Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.</description>
        </group>
        <group group_id="E3">
          <title>Filgrastim</title>
          <description>Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
Placebo №1: Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nose furunculus 3 grade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Left hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (4.03)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia any grade</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="43"/>
                <counts group_id="E3" events="41" subjects_affected="41" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Leucopenia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E2" events="38" subjects_affected="38" subjects_at_risk="43"/>
                <counts group_id="E3" events="41" subjects_affected="41" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness / asthenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="42"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Liver enzymes (ALT) elevation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hyperemia after injection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roman Ivanov, Director of Clinical Trials</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (812) 380 49 33 ext 950</phone>
      <email>ivanov@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

